home · filing · 0001104659-24-039882
8-K filed March 28, 2024, 7:59 PM ET
ticker ZURA
CIK 0001855644
leadership
confidence high
sentiment neutral
materiality 0.70
Zura Bio reports FY2023 net loss $60.4M, cash $99.8M, appoints Robert Lisicki as CEO
Zura Bio Ltd
Net loss of $60.4M for FY2023 vs $25.7M in FY2022; R&D expenses $44.0M, G&A $18.6M.
Cash and equivalents of $99.8M as of Dec 31, 2023, expected to fund operations into 2026.
Founder and CEO Someit Sidhu steps down; President Robert Lisicki appointed CEO effective April 8, 2024.
Sidhu remains on board as non-independent director; Board expands to ten members.
Plans to initiate Phase 2 trial of tibulizumab (ZB-106) for systemic sclerosis in 2H 2024.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Role change
Someit Sidhu
Chief Executive Officer
Effective 2024-04-08
Successor Robert Lisicki
Filed March 28, 2024, 7:59 PM ET
On March 24, 2024, the board of directors of ZURA (the “ Board ”) approved a Chief Executive Officer (“ CEO ”) transition from Someit Sidhu, our Founder, CEO and Director, to Robert Lisicki, effective April 8, 2024.
Appointed
Robert Lisicki
Director
Effective 2024-04-08
Filed March 28, 2024, 7:59 PM ET
Mr. Lisicki will join the Board as a non-independent Director increasing its membership from nine Directors to ten.
Role change
Robert Lisicki
Chief Executive Officer
Effective 2024-04-08
Filed March 28, 2024, 7:59 PM ET
Mr. Lisicki, the Company’s current President and Chief Operating Officer, will be promoted to the Company’s Chief Executive Officer on April 8, 2024.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.85
Zura Bio Ltd reported financial results for full year 2023.
Period full year 2023
Result reported results
Exact text from the filing
Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Someit Sidhu changed role as Chief Executive Officer at Zura Bio Ltd.
Action stepped down as CEO
Role Chief Executive Officer
Exact text from the filing
On March 24, 2024, the board of directors of ZURA (the “ Board ”) approved a Chief Executive Officer (“ CEO ”) transition from Someit Sidhu, our Founder, CEO and Director, to Robert Lisicki, effective April 8, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Robert Lisicki was appointed as Director at Zura Bio Ltd.
Action appointed
Role Director
Exact text from the filing
Mr. Lisicki will join the Board as a non-independent Director increasing its membership from nine Directors to ten.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Robert Lisicki changed role as Chief Executive Officer at Zura Bio Ltd.
Action promoted
Role Chief Executive Officer
Exact text from the filing
Mr. Lisicki, the Company’s current President and Chief Operating Officer, will be promoted to the Company’s Chief Executive Officer on April 8, 2024.
View on SEC.gov
Source: SEC EDGAR
accession 0001104659-24-039882
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.